Table 2.
Peripheral eosinophil counts before and after anti-IL-5/IL-5Rα mAb treatment and improvement of mucus plugs.
| Mucus plugs | p |
p (ANCOVA) |
||
|---|---|---|---|---|
| Improved | Not improved | |||
| Mepolizumab/Benralizumab | ||||
| n | 18 | 4 | ||
| Pre-treatment eosinophil counts, cells/μL |
1218 (527–2612) |
623 (114–3313) |
0.59 | 0.001 |
| Post-treatment eosinophil counts, cells/μL |
35 (0–61) |
233 (67–341) |
0.02 | |
| Eosinophil reduction rate, % |
98.5 (95.3–100) |
82.4 (34.5–89.1) |
0.001 | |
| Mepolizumab | ||||
| n | 13 | 4 | ||
| Pre-treatment eosinophil counts, cells/μL |
1303 (683–2938) |
623 (114–3313) |
0.41 | 0.001 |
| Post-treatment eosinophil counts, cells/μL |
48 (21–66) |
233 (67–341) |
0.08 | |
| Eosinophil reduction rate, % |
97.9 (90.7–98.8) |
82.4 (34.5–89.1) |
0.006 | |
Values are represented as the median (interquartile range).
AVCOVA analysis of covariance.